Skip to main content

Table 2 Overall best response among all treated patients by BICR

From: Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Response

Daratumumab 16 mg/kg (n = 32)

No.

%

95% CI

ORR

8

25.0

11.5–43.4

Clinical benefit rate (CR + PR + stable disease)

14

43.8

26.4–62.3

CR

0

0

 

PR

8

25.0

 

Stable disease

6

18.8

 

PD

14

43.8

 

NE

4

12.5

 
  1. BICR, blinded independent central review; CI, confidence interval; CR, complete response; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response